Skip to main content
Erschienen in: Journal of Neurology 3/2015

01.03.2015 | Original Communication

Substantia nigra hyperechogenicity in hypokinetic Huntington’s disease patients

verfasst von: Johann Lambeck, Wolf-Dirk Niesen, Reinhard Matthias, Cornelius Weiller, Dose Matthias, Zucker Birgit

Erschienen in: Journal of Neurology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Substantia nigra (SN) hyperechogenicity can be detected by transcranial sonography (TCS) to assist the early diagnosis of idiopathic Parkinson’s disease (IPD). This study prospectively investigated whether SN hyperechogenicity is also present in Huntington’s disease (HD) patients with symptoms of hypokinesia and/or rigidity. All patients recruited to the study (n = 15) were characterised by hypokinesia and/or rigidity while nine of these patients also displayed chorea and/or dystonia. The control group included 15 individuals. Clinical examination was documented using the Unified Huntington’s Disease Rating Scale (UHDRS). TCS examination revealed SN hyperechogenicity in 14/15 (93.3 %) patients (9/14 unilateral, 5/14 bilateral). Hyperechogenicity of the caudate and lentiform nuclei (CN, LN) was less frequent (CN: 80 % total, LN: 53.3 % total). This is the first study to assess SN hyperechogenicity in hypokinetic HD patients. Assuming that the primary sites of pathology in IPD and HD are the SN and the striatum, respectively, our observations suggest a functional impairment of the nigrostriatal system in HD, an effect that is potentially independent of the primarily-affected basal ganglia nucleus.
Literatur
1.
Zurück zum Zitat Walter U, Niehaus L, Probst T, Benecke R, Meyer BU, Dressler D (2003) Brain parenchyma sonography discriminates Parkinson’s disease and atypical parkinsonian syndromes. Neurology 60(1):74–77CrossRefPubMed Walter U, Niehaus L, Probst T, Benecke R, Meyer BU, Dressler D (2003) Brain parenchyma sonography discriminates Parkinson’s disease and atypical parkinsonian syndromes. Neurology 60(1):74–77CrossRefPubMed
2.
Zurück zum Zitat Hellwig S, Reinhard M, Amtage F, Guschlbauer B, Buchert R, Tuscher O, Weiller C, Niesen WD, Meyer PT (2014) Transcranial sonography and [18F]fluorodeoxyglucose positron emission tomography for the differential diagnosis of parkinsonism: a head-to-head comparison. Eur J Neurol 21(6):860–866CrossRefPubMed Hellwig S, Reinhard M, Amtage F, Guschlbauer B, Buchert R, Tuscher O, Weiller C, Niesen WD, Meyer PT (2014) Transcranial sonography and [18F]fluorodeoxyglucose positron emission tomography for the differential diagnosis of parkinsonism: a head-to-head comparison. Eur J Neurol 21(6):860–866CrossRefPubMed
3.
Zurück zum Zitat Berg D, Godau J, Walter U (2008) Transcranial sonography in movement disorders. Lancet Neurol 7(11):1044–1055CrossRefPubMed Berg D, Godau J, Walter U (2008) Transcranial sonography in movement disorders. Lancet Neurol 7(11):1044–1055CrossRefPubMed
4.
Zurück zum Zitat Walter U, Kanowski M, Kaufmann J, Grossmann A, Benecke R, Niehaus L (2008) Contemporary ultrasound systems allow high-resolution transcranial imaging of small echogenic deep intracranial structures similarly as MRI: a phantom study. Neuroimage. 40(2):551–558CrossRefPubMed Walter U, Kanowski M, Kaufmann J, Grossmann A, Benecke R, Niehaus L (2008) Contemporary ultrasound systems allow high-resolution transcranial imaging of small echogenic deep intracranial structures similarly as MRI: a phantom study. Neuroimage. 40(2):551–558CrossRefPubMed
5.
Zurück zum Zitat Sieradzan KA, Mann DM (2001) The selective vulnerability of nerve cells in Huntington’s disease. Neuropathol Appl Neurobiol 27(1):1–21CrossRefPubMed Sieradzan KA, Mann DM (2001) The selective vulnerability of nerve cells in Huntington’s disease. Neuropathol Appl Neurobiol 27(1):1–21CrossRefPubMed
6.
Zurück zum Zitat Phillips W, Shannon KM, Barker RA (2008) The current clinical management of Huntington’s disease. Mov Disord 23(11):1491–1504CrossRefPubMed Phillips W, Shannon KM, Barker RA (2008) The current clinical management of Huntington’s disease. Mov Disord 23(11):1491–1504CrossRefPubMed
7.
Zurück zum Zitat Bittenbender JB, Quadfasel FA (1962) Rigid and akinetic forms of Huntington’s chorea. Arch Neurol 7:275–288CrossRefPubMed Bittenbender JB, Quadfasel FA (1962) Rigid and akinetic forms of Huntington’s chorea. Arch Neurol 7:275–288CrossRefPubMed
8.
Zurück zum Zitat Postert T, Lack B, Kuhn W, Jergas M, Andrich J, Braun B, Przuntek H, Sprengelmeyer R, Agelink M, Buttner T (1999) Basal ganglia alterations and brain atrophy in Huntington’s disease depicted by transcranial real time sonography. J Neurol Neurosurg Psychiatry 67(4):457–462PubMedCentralCrossRefPubMed Postert T, Lack B, Kuhn W, Jergas M, Andrich J, Braun B, Przuntek H, Sprengelmeyer R, Agelink M, Buttner T (1999) Basal ganglia alterations and brain atrophy in Huntington’s disease depicted by transcranial real time sonography. J Neurol Neurosurg Psychiatry 67(4):457–462PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Krogias C, Strassburger K, Eyding J, Gold R, Norra C, Juckel G, Saft C, Ninphius D (2011) Depression in patients with Huntington disease correlates with alterations of the brain stem raphe depicted by transcranial sonography. J Psychiatry Neurosci 36(3):187–194PubMedCentralCrossRefPubMed Krogias C, Strassburger K, Eyding J, Gold R, Norra C, Juckel G, Saft C, Ninphius D (2011) Depression in patients with Huntington disease correlates with alterations of the brain stem raphe depicted by transcranial sonography. J Psychiatry Neurosci 36(3):187–194PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Hsg (1996) Unified Huntington’s Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord 11(2):136–142CrossRef Hsg (1996) Unified Huntington’s Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord 11(2):136–142CrossRef
11.
Zurück zum Zitat Walter U, Behnke S, Eyding J, Niehaus L, Postert T, Seidel G, Berg D (2007) Transcranial brain parenchyma sonography in movement disorders: state of the art. Ultrasound Med Biol 33(1):15–25CrossRefPubMed Walter U, Behnke S, Eyding J, Niehaus L, Postert T, Seidel G, Berg D (2007) Transcranial brain parenchyma sonography in movement disorders: state of the art. Ultrasound Med Biol 33(1):15–25CrossRefPubMed
12.
Zurück zum Zitat Berg D, Jabs B, Merschdorf U, Beckmann H, Becker G (2001) Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy. Biol Psychiatry 50(6):463–467CrossRefPubMed Berg D, Jabs B, Merschdorf U, Beckmann H, Becker G (2001) Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy. Biol Psychiatry 50(6):463–467CrossRefPubMed
13.
Zurück zum Zitat Berardelli A, Noth J, Thompson PD, Bollen EL, Curra A, Deuschl G, Van Dijk JG, Topper R, Schwarz M, Roos RA (1999) Pathophysiology of chorea and bradykinesia in Huntington’s disease. Mov Disord 14(3):398–403CrossRefPubMed Berardelli A, Noth J, Thompson PD, Bollen EL, Curra A, Deuschl G, Van Dijk JG, Topper R, Schwarz M, Roos RA (1999) Pathophysiology of chorea and bradykinesia in Huntington’s disease. Mov Disord 14(3):398–403CrossRefPubMed
14.
Zurück zum Zitat Thompson PD, Berardelli A, Rothwell JC, Day BL, Dick JP, Benecke R, Marsden CD (1988) The coexistence of bradykinesia and chorea in Huntington’s disease and its implications for theories of basal ganglia control of movement. Brain 111(Pt 2):223–244CrossRefPubMed Thompson PD, Berardelli A, Rothwell JC, Day BL, Dick JP, Benecke R, Marsden CD (1988) The coexistence of bradykinesia and chorea in Huntington’s disease and its implications for theories of basal ganglia control of movement. Brain 111(Pt 2):223–244CrossRefPubMed
15.
Zurück zum Zitat Schweitzer KJ, Hilker R, Walter U, Burghaus L, Berg D (2006) Substantia nigra hyperechogenicity as a marker of predisposition and slower progression in Parkinson’s disease. Mov Disord 21(1):94–98CrossRefPubMed Schweitzer KJ, Hilker R, Walter U, Burghaus L, Berg D (2006) Substantia nigra hyperechogenicity as a marker of predisposition and slower progression in Parkinson’s disease. Mov Disord 21(1):94–98CrossRefPubMed
16.
Zurück zum Zitat Berg D, Roggendorf W, Schroder U, Klein R, Tatschner T, Benz P, Tucha O, Preier M, Lange KW, Reiners K, Gerlach M, Becker G (2002) Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 59(6):999–1005CrossRefPubMed Berg D, Roggendorf W, Schroder U, Klein R, Tatschner T, Benz P, Tucha O, Preier M, Lange KW, Reiners K, Gerlach M, Becker G (2002) Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 59(6):999–1005CrossRefPubMed
17.
Zurück zum Zitat Lumsden AL, Henshall TL, Dayan S, Lardelli MT, Richards RI (2007) Huntingtin-deficient zebrafish exhibit defects in iron utilization and development. Hum Mol Genet 16(16):1905–1920CrossRefPubMed Lumsden AL, Henshall TL, Dayan S, Lardelli MT, Richards RI (2007) Huntingtin-deficient zebrafish exhibit defects in iron utilization and development. Hum Mol Genet 16(16):1905–1920CrossRefPubMed
18.
Zurück zum Zitat Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson’s disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114(Pt 4):1953–1975CrossRefPubMed Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson’s disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114(Pt 4):1953–1975CrossRefPubMed
19.
Zurück zum Zitat Rosas HD, Chen YI, Doros G, Salat DH, Chen NK, Kwong KK, Bush A, Fox J, Hersch SM (2012) Alterations in brain transition metals in Huntington disease: an evolving and intricate story. Arch Neurol 69(7):887–893PubMedCentralCrossRefPubMed Rosas HD, Chen YI, Doros G, Salat DH, Chen NK, Kwong KK, Bush A, Fox J, Hersch SM (2012) Alterations in brain transition metals in Huntington disease: an evolving and intricate story. Arch Neurol 69(7):887–893PubMedCentralCrossRefPubMed
20.
Zurück zum Zitat Muller M, Leavitt BR (2014) Iron dysregulation in Huntington’s disease. J Neurochem 130:328–350CrossRefPubMed Muller M, Leavitt BR (2014) Iron dysregulation in Huntington’s disease. J Neurochem 130:328–350CrossRefPubMed
21.
Zurück zum Zitat Jellinger KA (2013) The relevance of metals in the pathophysiology of neurodegeneration, pathological considerations. Int Rev Neurobiol 110:1–47CrossRefPubMed Jellinger KA (2013) The relevance of metals in the pathophysiology of neurodegeneration, pathological considerations. Int Rev Neurobiol 110:1–47CrossRefPubMed
22.
Zurück zum Zitat Jabs BE, Berg D, Merschdorf U, Bartsch AJ, Pfuhlmann B (2001) Differences in substantia nigra echogenicity of nosological subtypes within the schizophrenic spectrum. A preliminary transcranial ultrasound study. Neuropsychobiology 44(4):183–186CrossRefPubMed Jabs BE, Berg D, Merschdorf U, Bartsch AJ, Pfuhlmann B (2001) Differences in substantia nigra echogenicity of nosological subtypes within the schizophrenic spectrum. A preliminary transcranial ultrasound study. Neuropsychobiology 44(4):183–186CrossRefPubMed
23.
Zurück zum Zitat Behnke S, Runkel A, Kassar HA, Ortmann M, Guidez D, Dillmann U, Fassbender K, Spiegel J (2013) Long-term course of substantia nigra hyperechogenicity in Parkinson’s disease. Mov Disord 28(4):455–459CrossRefPubMed Behnke S, Runkel A, Kassar HA, Ortmann M, Guidez D, Dillmann U, Fassbender K, Spiegel J (2013) Long-term course of substantia nigra hyperechogenicity in Parkinson’s disease. Mov Disord 28(4):455–459CrossRefPubMed
Metadaten
Titel
Substantia nigra hyperechogenicity in hypokinetic Huntington’s disease patients
verfasst von
Johann Lambeck
Wolf-Dirk Niesen
Reinhard Matthias
Cornelius Weiller
Dose Matthias
Zucker Birgit
Publikationsdatum
01.03.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 3/2015
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-014-7587-1

Weitere Artikel der Ausgabe 3/2015

Journal of Neurology 3/2015 Zur Ausgabe

Pioneers in Neurology

Otto Poetzl (1877–1962)

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.